|1.||Fazio, Nicola: 2 articles (09/2008 - 04/2007)|
|2.||Seminara, P: 2 articles (12/2001 - 12/2001)|
|3.||Gargano, L: 2 articles (12/2001 - 12/2001)|
|4.||Franchi, F: 2 articles (12/2001 - 12/2001)|
|5.||Fujii, Masashi: 1 article (09/2014)|
|6.||Nakajima, Toshifusa: 1 article (09/2014)|
|7.||Boc, Marko: 1 article (06/2012)|
|8.||Skof, Erik: 1 article (06/2012)|
|9.||Hlebanja, Zvezdana: 1 article (06/2012)|
|10.||Ocvirk, Janja: 1 article (06/2012)|
|1.||Stomach Neoplasms (Stomach Cancer)
06/01/2012 - "The ECX regimen was at least as effective as the ECF regimen with a similar tolerability profile, and could therefore replace the ECF regimen for the first-line treatment of patients with advanced gastric cancer."
11/15/1995 - "This study found that the ECF regimen is substantially active in treating patients with advanced gastric cancer and has a favorable pattern of toxicity. "
01/01/2012 - "A modified ECF regimen may be an effective and convenient treatment with tolerable toxicities for the adjuvant treatment of gastric cancer. "
09/01/1994 - "The ECF regimen displays high anti-tumour activity with moderate toxicity in patients with gastric cancer and in some cases enabled resection of previously inoperable tumours."
01/01/1998 - "In addition the Medical Research Council are conducting a trial randomising patients between surgery alone and perioperative chemotherapy using the ECF regimen in operable gastric cancer."
01/01/2007 - "As a therapeutic option, a combination therapy using ECF regimen may provide a significantly better tumor response and survival benefit in patients with large HCC invading the portal vein."
06/01/2002 - "Overall, the ECF regimen showed high anti-tumor activity with a tolerable toxicity pattern."
11/01/1992 - "Significantly higher survival rates were demonstrated in those patients with recurrent cancers (p < 0.01) and those who responded to the FPEPIR regimen (p < 0.05). "
04/01/2011 - "In patients with advanced gastroesophageal cancer, the phase iii Randomized ECF for Advanced and Locally Advanced Esophagogastric Cancer 2 (real-2) trial demonstrated equivalent clinical efficacy when capecitabine (x) was substituted for 5-fluorouracil (5fu) in the epirubicin-cisplatin-5fu (ecf) regimen. "
04/01/1999 - "We report the final results of a prospectively randomized study that compared the combination of epirubicin, cisplatin and protracted venous infusion fluorouracil (5-FU) (ECF regimen) with the standard combination of 5-FU, doxorubicin and methotrexate (FAMTX) in previously untreated patients with advanced oesophagogastric cancer. "
04/01/2007 - "Adjuvant chemotherapy (ECF regimen) for patients with gastric adenocarcinoma."
02/01/2012 - "In recent years, based on the phase III clinical study, postoperative chemoradiation, perioperative chemotherapy with ECF regimen and postoperative adjuvant chemotherapy with oral S-1 have become the standard adjuvant treatment of resectable gastric adenocarcinoma in the United States, Europe, and Japan, respectively. "
|4.||Pancreatic Neoplasms (Pancreatic Cancer)
|5.||Breast Neoplasms (Breast Cancer)
|7.||Leucovorin (Folinic Acid)
|1.||Drug Therapy (Chemotherapy)
|4.||Combination Drug Therapy (Combination Chemotherapy)